UK Markets closed

CureVac N.V. (CVAC)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
55.30+1.71 (+3.19%)
As of 4:00PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close53.59
Open54.00
Bid54.51 x 900
Ask55.33 x 1200
Day's range52.83 - 55.67
52-week range44.45 - 151.80
Volume358,552
Avg. volume728,361
Market cap10.298B
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • EQS Group

    CureVac Streamlines European Network for mRNA Product Manufacturing

    DGAP-News: CureVac / Key word(s): Alliance14.09.2021 / 13:19 The issuer is solely responsible for the content of this announcement.CureVac Streamlines European Network for mRNA Product Manufacturing CureVac right-sizes manufacturing network to adapt to changes in vaccine peak demands Demand reassessed for first-generation COVID-19 vaccine candidate, CVnCoV, currently under regulatory review with EMA Contracts with manufacturing partners WACKER and Celonic terminated; Rentschler Biopharma and Nov

  • EQS Group

    CureVac Announces Financial Results for the Second Quarter and First Half of 2021 and Provides Business Update

    DGAP-News: CureVac / Key word(s): Quarter Results/Half Year Results16.08.2021 / 13:10 The issuer is solely responsible for the content of this announcement.CureVac Announces Financial Results for the Second Quarter and First Half of 2021 and Provides Business Update Continuation of corporate transformation into commercial-ready biopharma company Management team strengthened with appointments of Chief Operating Officer Malte Greune and Chief Development Officer Klaus Edvardsen First-generation CO

  • EQS Group

    CureVac : Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study

    DGAP-News: CureVac / Key word(s): Study results/Study16.08.2021 / 13:00 The issuer is solely responsible for the content of this announcement.Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study Preclinical study provides evidence for strongly improved immune responses with second-generation mRNA backbone jointly developed by CureVac and GSK compared to CureVac's first-generation mRNA backbone Data demonstrate high p